Skip to content

On this page

Uplizna

inebilizumab-cdon

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Uplizna

Proper name

inebilizumab-cdon

Licence type

351(a)

BLA number

761142

Applicant

Horizon Therapeutics Ireland DAC

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
100MG/10ML (10MG/ML)	Injection	Intravenous	Single-Dose Vial	Rx	June 11, 2020

Exclusivity

Source: Purple Book

Kind	Expires
Orphan exclusivity	June 11, 2027

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity